Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX TWISTHALER versus EMFLAZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX TWISTHALER versus EMFLAZA.
ASMANEX TWISTHALER vs EMFLAZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators (e.g., cytokines, chemokines, adhesion molecules) and suppression of inflammatory cell migration and activation in the airways.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
Inhalation: 1-2 inhalations twice daily (morning and evening). Typical adult dose: 200-400 mcg twice daily. Maximum: 800 mcg/day.
0.6 mg/kg orally once daily (maximum 60 mg/day); titrate to lowest effective dose based on clinical response.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation via ASMANEX TWISTHALER is approximately 5 hours (range 4–6 hours) in patients with asthma. This relatively short half-life supports twice-daily or once-daily dosing with sustained clinical effect due to prolonged local retention in the lungs.
6.2 hours (range 4.5–8.1 h) in healthy adults; prolonged in hepatic impairment.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver via CYP3A4. Unchanged drug and metabolites are excreted primarily in the feces via biliary elimination (approximately 74% of a single oral dose) and to a minor extent in the urine (approximately 8%). For inhaled doses, renal excretion of unchanged drug is negligible (<1% of administered dose).
Renal excretion of inactive metabolites; less than 5% excreted as unchanged drug in urine. Biliary/fecal elimination accounts for <1%.
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid